title: The determination of Q192R polymorphism of paraoxonase 1 by using non-toxic substrate p-nitrophenylacetate.
abstract: BACKGROUND
  The human serum paraoxonase 1 (PON1) is calcium-dependent esterase and associates with the high density serum lipoproteins. PON1 plays a major role in oxidation of high density lipoprotein and low density lipoprotein and prevention of atherogenesis in coronary heart disease. PON1Q and R allele hydrolyses number of substrates like paraoxon (PO) (diethyl p-nitrophenyl phosphate) and phenylacetate.
  
  
  OBJECTIVE
  The aim of the study is to the determination of Q192R polymorphism of PON1 by using non-toxic substrate p-nitrophenylacetate and compares it with the phenotype determined by using PO as substrate.
  
  
  METHODS
  The study group consists of 60 healthy normal patients. Paraoxonase activity was measured using the procedure described by Eckerson (Reference method) and for phenotyping; the ratio of hydrolysis of PO in the presence of 1 M NaCl (salt-stimulated PON1, SALT) to the hydrolysis of phenylacetate (PA) is calculated. In new method (Haagen et al.) arylesterase activity measured using p-nitrophenylacetate and for phenotyping arylesterase, the ratio of inhibition of enzymatic hydrolysis of p-nitrophenylacetate (substrate) by phenyl acetate to non-inhibited hydrolysis of p-nitrophenylacetate (inhibited arylesterase activity (IA-IA0)/non-inhibited arylesterase activity (NIA).
  
  
  RESULTS
  It was found that paraoxonase activity is trimodally distributed in both the methods. There is no significant difference in the distribution of PON1 phenotypes of both reference method and new method being frequencies 0.946 and 0.376 respectively and there was no significant difference for phenotypic polymorphism for an individual by both methods (χ(2)= 0.15 and P = 0.9262).
  
  
  CONCLUSIONS
  The Q192R polymorphism of PON1 by using non-toxic substrate p-nitrophenylacetate showed trimodal distribution of QQ (homozygous), QR (heterozygous), and RR (homozygous) phenotype and it is comparable with reference method. This method can be used for PON1 phenotype in different pathological and complex disease conditions.
authors.affiliation: Department of Biochemistry, SRTR Government Medical College, Ambajogai, Maharashtra, India.
authors.forename: M R
authors.initials: MR
authors.lastname: Mogarekar
authors.forename: Seema S
authors.initials: SS
authors.lastname: Chawhan
keywords: Paraoxonase 1 polymorphism; arylesterase; p-nitrophenylacetate; paraoxon
references.citation: Genomics. 1996 May 1;33(3):498-507
references.pmid: 8661009
references.citation: Hepatogastroenterology. 2003 Dec;50 Suppl 2:cclxxiii-cclxxv
references.pmid: 15244199
references.citation: Psychiatr Genet. 2008 Dec;18(6):289-94
references.pmid: 19018234
references.citation: Drug Metab Dispos. 1991 Jan-Feb;19(1):100-6
references.pmid: 1673382
references.citation: J Am Soc Nephrol. 1998 Nov;9(11):2082-8
references.pmid: 9808094
references.citation: J Clin Invest. 1998 Apr 15;101(8):1581-90
references.pmid: 9541487
references.citation: FEBS Lett. 1998 Feb 13;423(1):57-60
references.pmid: 9506841
references.citation: Curr Opin Lipidol. 2004 Aug;15(4):399-404
references.pmid: 15243212
references.citation: Hepatogastroenterology. 2003 Dec;50 Suppl 2:ccxxv-ccxxvii
references.pmid: 15244186
references.citation: FEBS Lett. 1991 Jul 29;286(1-2):152-4
references.pmid: 1650712
references.citation: Circulation. 2000 May 30;101(21):2510-7
references.pmid: 10831526
references.citation: Ann N Y Acad Sci. 2002 Nov;977:239-44
references.pmid: 12480756
references.citation: Eur J Clin Chem Clin Biochem. 1992 Jul;30(7):391-5
references.pmid: 1525262
references.citation: Nat Genet. 1996 Nov;14(3):334-6
references.pmid: 8896566
references.citation: Pharmacogenomics. 2002 May;3(3):341-8
references.pmid: 12052142
references.citation: Arterioscler Thromb Vasc Biol. 2000 Nov;20(11):2441-7
references.pmid: 11073850
references.citation: Arterioscler Thromb Vasc Biol. 1995 Nov;15(11):1812-8
references.pmid: 7583560
references.citation: Chem Biol Interact. 1999 May 14;119-120:379-88
references.pmid: 10421474
references.citation: Pharmacogenetics. 1999 Dec;9(6):745-53
references.pmid: 10634137
references.citation: Arterioscler Thromb Vasc Biol. 1999 Feb;19(2):330-5
references.pmid: 9974415
references.citation: Am J Hum Genet. 1983 Nov;35(6):1126-38
references.pmid: 6316781
references.citation: Biochem Biophys Res Commun. 2007 Dec 7;364(1):157-62
references.pmid: 17936248
references.citation: J Prev Med Public Health. 2005 Aug;38(3):345-50
references.pmid: 16323636
references.citation: Lancet. 1994 Sep 17;344(8925):796-8
references.pmid: 7916079
references.citation: Circ Cardiovasc Genet. 2008 Dec;1(2):147-52
references.pmid: 20031556
references.citation: Nat Genet. 1993 Jan;3(1):73-6
references.pmid: 8098250
references.citation: Metabolism. 1998 May;47(5):598-602
references.pmid: 9591753
references.citation: Ann Med. 1999 Jun;31(3):217-24
references.pmid: 10442677
references.citation: Am J Hum Genet. 1988 Sep;43(3):230-8
references.pmid: 2458038
references.citation: Lancet. 1995 Sep 30;346(8979):869-72
references.pmid: 7564671
references.citation: Curr Opin Lipidol. 1996 Apr;7(2):69-76
references.pmid: 8743898
references.citation: Arterioscler Thromb Vasc Biol. 2001 Apr;21(4):473-80
references.pmid: 11304460
references.citation: Am J Hum Genet. 1993 Mar;52(3):598-608
references.pmid: 7916578
references.citation: J Hum Genet. 2004;49(9):474-481
references.pmid: 15368102
references.citation: Arterioscler Thromb Vasc Biol. 2001 Sep;21(9):1451-7
references.pmid: 11557671
references.citation: Annu Rev Med. 2003;54:371-92
references.pmid: 12525679
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):78-88
references.pmid: 14579013
references.citation: Physiol Res. 2008;57(5):717-726
references.pmid: 17949258